SLC5A2 and diabetic kidney disease: Since the 1990s, the progression of DKD has been slowed by specific therapies, such as RAAS blockers (including ACE inhibitors and ARBs), non-steroidal MR antagonists (e.g., finerenone), and SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, and tofogliflozin) (Figure 5) [379].